Showing 3371-3380 of 3506 results for "".
- La Roche-Posay's "Dermatologist from the Heart" Accepting Applicationshttps://practicaldermatology.com/news/20140421-la_roche-posays_dermatologist_from_the_heart_accepting_applications/2459264/La Roche-Posay is accepting grant application for its “Dermatologist from the Heart” program in the United States. Now in its second year in the US, “Dermatologist from the Heart” aims to support initiatives designed to enhance the quality of life for patients. Through this program, the La Fon
- Presentation: PV-10 decreases Melanoma Cells in Tumors and Boosts T-Cellshttps://practicaldermatology.com/news/20140407-presentation_pv-10_decreases_melanoma_cells_in_tumors_and_boosts_t-cells/2459277/Treatment with Provectus Biopharmaceuticals, Inc.'s PV-10 produces a significant decrease in melanoma cells in tumors 7-14 days after treatment, new data show. The data were presented by researchers at the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Sa
- International Society of Hair Restoration Surgery Achieves ACCME Accreditation With Commendation for Educational Activitieshttps://practicaldermatology.com/news/20140401-international_society_of_hair_restoration_surgery__achieves_accme_accreditation_with_commendation_for_educational_activities/2459284/The International Society of Hair Restoration Surgery (ISHRS) – the largest international medical association of hair restoration surgeons – announced today that the Accreditation Council for Continuing Medical Education (ACCME) awarded the ISHRS Accreditation with Commendation for six years as a pr
- Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexeshttps://practicaldermatology.com/news/20140401-revance_therapeutics_added_to_russell_2000r_and_3000r_indexes/2459286/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
- Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanomahttps://practicaldermatology.com/news/20140325-provectus_biopharmaceuticals_inc_submits_application_to_fda_to_receive_breakthrough_therapy_designation_for_pv-10_for_treatment_of_melanoma/2459296/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal a
- FDA approves Impavido to treat tropical disease leishmaniasishttps://practicaldermatology.com/news/20140320-fda_approves_impavido_to_treat_tropical_disease_leishmaniasis/2459308/The US Food and Drug Administration approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites. The disease occurs primarily in people who live in the tropics and
- Foamix, Ltd. Will Present Phase II Results for Topical Minocycline at Upcoming Conferencehttps://practicaldermatology.com/news/20140227-foamix_ltd_will_present_phase_2_results_for_topical_minocycline_at_upcoming_conference/2459328/Foamix will present the successful results from its Phase II clinical trials with topical minocycline for acne and impetigo at the 34th Annual Cowen & Company Health Care Conference. The pharmaceutical company, which focuses on the development of patented topical foams for de
- Eclipse Sun Launches New Line of Sun Protective Clothing for Babies and Kidshttps://practicaldermatology.com/news/20140220-eclipse_sun_launches_new_line_of_sun_protective_clothing_for_babies_and_kids/2459336/Eclipse Sun Products announced the introduction of its new line of sun protective clothing made especially for babies and kids. The
- Support Camp Discovery: Follow Us on Twitterhttps://practicaldermatology.com/news/20140130-support_camp_discovery_follow_us_on_twitter/2459354/Practical Dermatology® is excited to announce that we'll donate 20 cents for every new Twitter follower from Jan. 31, 2014 through March 14, 2014* to Camp Discovery. Simply follow @Practical_Derm on Twitte